DCV 3DAA FDC

DRUG5 trials

Sponsors

Bristol-Myers Squibb

Conditions

Hepatitis CHepatitis C Infection

Phase 1

Drug Interaction & Methadone & Buprenorphine

CompletedNCT02045693

Bristol-Myers SquibbHepatitis C

Start: 2014-02-28End: 2014-04-30Updated: 2014-06-17

Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects

CompletedNCT02045966

Bristol-Myers SquibbHepatitis C

Start: 2014-02-28End: 2014-04-30Updated: 2014-06-17

Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325

CompletedNCT02095860

Bristol-Myers SquibbHepatitis C

Start: 2014-04-30End: 2014-05-31Updated: 2014-10-10

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

CompletedNCT02108639

Bristol-Myers SquibbHepatitis C

Start: 2014-04-30End: 2014-06-30Updated: 2014-07-10

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

CompletedNCT02175602

Bristol-Myers SquibbHepatitis C Infection

Start: 2014-06-30Updated: 2015-02-10